The outlook of companies tied to Viagra's past presents a intricate investment landscape. While the initial boom generated substantial profits , generic copies have significantly eroded sales . Investing in connected pharmaceutical firms now requires a careful assessment of proprietary protection , evolving medical changes, and the potential for br